This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Exelixis Provides Preliminary 2024 Results and Outlook for 2025
by Zacks Equity Research
EXEL reports preliminary 2024 revenues. The company also provides guidance for 2025 and other pipeline updates.
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
by Zacks Equity Research
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
FDA Updates EXEL on Previously Scheduled ODAC Meeting for Cabozantinib
by Zacks Equity Research
EXEL's sNDA seeking approval of cabozantinib for the treatment of pancreatic neuroendocrine tumors will not be discussed at an ODAC.
Bristol Myers Stock Gains 11.4% in a Year: Time to Buy or Sell?
by Ekta Bagri
Bristol Myers stock has performed well in the past year, gaining 11%. We believe there is more room for further growth, and any dip in the share price can be used as a buying opportunity.
Merck (MRK) Rises Higher Than Market: Key Facts
by Zacks Equity Research
Merck (MRK) closed at $99.72 in the latest trading session, marking a +0.59% move from the prior day.
Exelixis Stock Surges 50% in a Year: Is There Room for Further Growth?
by Zacks Equity Research
EXEL's shares surge 50% in a year on the back of the strong performance of its lead drug Cabometyx. We are optimistic about the stock as we believe there is room for further growth.
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Should iShares MSCI USA Min Vol Factor ETF (USMV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for USMV
VKTX Stock Loses More Than 20% in Six Months: Should You Buy the Dip?
by Sundeep Ganoria
Despite the rising competition in the obesity space, we believe that there is room for smaller biotechs like Viking Therapeutics to grab a share of this booming market.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Merck (MRK) Sees a More Significant Dip Than Broader Market: Some Facts to Know
by Zacks Equity Research
The latest trading day saw Merck (MRK) settling at $98.37, representing a -1.33% change from its previous close.
AZN, Daiichi Withdraw EU Filing for Dato-DXd in Nonsquamous NSCLC
by Zacks Equity Research
AstraZeneca and Daiichi Sankyo voluntarily withdraw regulatory filing for Dato-DXd in nonsquamous non-small cell lung cancer in the European Union.
Merck (MRK) Rises Yet Lags Behind Market: Some Facts Worth Knowing
by Zacks Equity Research
Merck (MRK) closed the most recent trading day at $99.45, moving +0.08% from the previous trading session.
Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III
by Zacks Equity Research
SNY begins phase III study for its 21-valent pneumococcal conjugate vaccine for treating invasive pneumococcal disease in infants and toddlers.
NVO Stock Plunges as Obesity Drug CagriSema Misses Target in Phase III
by Zacks Equity Research
Novo Nordisk stock slumps as the 22.7% weight loss achieved with its next-gen obesity candidate, CagriSema, in a phase III study misses its guidance of 25%.
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?
by Sundeep Ganoria
Shares of MRNA have been declining after it lowered its long-term financial guidance. It has also pushed its breakeven point by another two years to 2028.
Gilead Stock Gains 15.4% in a Year: Should You Buy, Sell or Hold?
by Ekta Bagri
GILD has put up a steady performance in 2024, with a new drug approval, positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.
MRK's Pivotal Study on Two-Drug, Once-Daily HIV Pill Meets Goals
by Zacks Equity Research
Merck posts positive data from two phase III studies evaluating a two-drug, single-tablet regimen of doravirine/islatravir in adults with HIV-1 infection.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals
by Kinjel Shah
PFE issues its financial guidance for 2025. MRK and ABBV announce M&A deals. SNY/TEVA's IBD drug succeeds in a phase IIb study.
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug
by Zacks Equity Research
Merck gets exclusive global rights to develop, manufacture and commercialize GLP-1 receptor agonist, HS-10535, from Hansoh Pharma.
Here's Why VKTX Stock Plummeted 18% on Wednesday
by Zacks Equity Research
The selloff in Viking Therapeutics stock comes after some investors raised concerns for the small biotech amid Merck's entry into the obesity space.
Merck (MRK) Stock Moves -1.72%: What You Should Know
by Zacks Equity Research
In the latest trading session, Merck (MRK) closed at $98.34, marking a -1.72% move from the previous day.
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts MRK's BLA for clesrovimab, its monoclonal antibody, to protect infants from RSV disease. A decision from the agency is due on June 10, 2025.
Merck to End Development of Two Cancer Candidates: Time to Sell?
by Kinjel Shah
We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider selling the same.